OOIR: Observatory of International Research

Papers

(The TQCC of Journal of Medical Virology is 12. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
The cytokine storm and COVID‐19	955
Postdischarge symptoms and rehabilitation needs in survivors of COVID‐19 infection: A cross‐sectional evaluation	922
Central nervous system involvement by severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2)	710
Omicron variant of SARS‐CoV‐2: Genomics, transmissibility, and responses to current COVID‐19 vaccines	571
The impact of COPD and smoking history on the severity of COVID‐19: A systemic review and meta‐analysis	485
Predictors of mortality in hospitalized COVID‐19 patients: A systematic review and meta‐analysis	430
Clinical characteristics of 3062 COVID‐19 patients: A meta‐analysis	411
Epidemiology of COVID‐19: A systematic review and meta‐analysis of clinical characteristics, risk factors, and outcomes	405
Elevated interleukin‐6 and severe COVID‐19: A meta‐analysis	401
Omicron and Delta variant of SARS‐CoV‐2: A comparative computational study of spike protein	393
False negative of RT‐PCR and prolonged nucleic acid conversion in COVID‐19: Rather than recurrence	377
In silico studies on the comparative characterization of the interactions of SARS‐CoV‐2 spike glycoprotein with ACE‐2 receptor homologs and human TLRs	337
The emergence and epidemic characteristics of the highly mutated SARS‐CoV‐2 Omicron variant	327
Post‐acute COVID‐19 syndrome (PCS) and health‐related quality of life (HRQoL)—A systematic review and meta‐analysis	327
Vaccine hesitancy: Beliefs and barriers associated with COVID‐19 vaccination among Egyptian medical students	292
Proportion of asymptomatic coronavirus disease 2019: A systematic review and meta‐analysis	288
Treatment with convalescent plasma for COVID‐19 patients in Wuhan, China	286
The effect of smoking on COVID‐19 severity: A systematic review and meta‐analysis	278
Role of Toll‐like receptors in the pathogenesis of COVID‐19	251
A systematic review and meta‐analysis of children with coronavirus disease 2019 (COVID‐19)	236
Convalescent plasma transfusion for the treatment of COVID‐19: Systematic review	219
Elevated level of C‐reactive protein may be an early marker to predict risk for severity of COVID‐19	219
Hypoalbuminemia predicts the outcome of COVID‐19 independent of age and co‐morbidity	217
Characterization of the novel SARS‐CoV‐2 Omicron (B.1.1.529) variant of concern and its global perspective	211
Obesity aggravates COVID‐19: A systematic review and meta‐analysis	204

OMICRON (B.1.1.529): A new SARS‐CoV‐2 variant of concern mounting worldwide fear	198
Current evidence on efficacy of COVID‐19 booster dose vaccination against the Omicron variant: A systematic review	191
Evaluation of sex‐related hormones and semen characteristics in reproductive‐aged male COVID‐19 patients	186
A comparison study of SARS‐CoV‐2 IgG antibody between male and female COVID‐19 patients: A possible reason underlying different outcome between sex	181
Sequence analysis of the emerging SARS‐CoV‐2 variant Omicron in South Africa	173
Epidemiological trends and clinical features of the ongoing monkeypox epidemic: A preliminary pooled data analysis and literature review	172
The value of clinical parameters in predicting the severity of COVID‐19	172
Psychological stress of medical staffs during outbreak of COVID‐19 and adjustment strategy	171
Coinfection in SARS‐CoV‐2 infected patients: Where are influenza virus and rhinovirus/enterovirus?	170
Tocilizumab for the treatment of severe coronavirus disease 2019	169
Chronic COVID syndrome: Need for an appropriate medical terminology for long‐COVID and COVID long‐haulers	160
Relative instantaneous reproduction number of Omicron SARS‐CoV‐2 variant with respect to the Delta variant in Denmark	159
Detection profile of SARS‐CoV‐2 using RT‐PCR in different types of clinical specimens: A systematic review and meta‐analysis	159
A brief review of influenza virus infection	158
Emerging coronaviruses: Genome structure, replication, and pathogenesis	153
Omicron variant (B.1.1.529) of SARS‐CoV‐2, a global urgent public health alert!	149
Evaluation of SARS‐CoV‐2 neutralizing antibodies using a CPE‐based colorimetric live virus micro‐neutralization assay in human serum samples	149
SARS‐CoV‐2 ORF9b antagonizes type I and III interferons by targeting multiple components of the RIG‐I/MDA‐5–MAVS, TLR3–TRIF, and cGAS–STING signaling pathways	147
Prolonged SARS‐CoV‐2 RNA shedding: Not a rare phenomenon	142
Omicron variant genome evolution and phylogenetics	141
Encephalopathy in patients with COVID‐19: A review	140
Clinical characteristics and outcomes of cancer patients with COVID‐19	140
Virological and clinical cure in COVID‐19 patients treated with hydroxychloroquine: A systematic review and meta‐analysis	140
Should RT‐PCR be considered a gold standard in the diagnosis of COVID‐19?	139
Characteristics of patients with coronavirus disease (COVID‐19) confirmed using an IgM‐IgG antibody test	137
Estimation of the basic reproduction number, average incubation time, asymptomatic infection rate, and case fatality rate for COVID‐19: Meta‐analysis and sensitivity analysis	135
A large‐scale meta‐analytic atlas of mental health problems prevalence during the COVID‐19 early pandemic	131
The epidemiology and clinical characteristics of co‐infection of SARS‐CoV‐2 and influenza viruses in patients during COVID‐19 outbreak	129
Vitamin D insufficiency as a potential culprit in critical COVID‐19 patients	127
High IL‐6/IFN‐γ ratio could be associated with severe disease in COVID‐19 patients	126
Preliminary report on severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) Spike mutation T478K	122
Mathematical modeling of interaction between innate and adaptive immune responses in COVID‐19 and implications for viral pathogenesis	122
Neutrophil to lymphocyte ratio as prognostic and predictive factor in patients with coronavirus disease 2019: A retrospective cross‐sectional study	121
Emergence of Omicron third lineage BA.3 and its importance	120
Diagnostic accuracy of an automated chemiluminescent immunoassay for anti‐SARS‐CoV‐2 IgM and IgG antibodies: an Italian experience	119
Analysis of 92 deceased patients with COVID‐19	119
Impaired glucose metabolism in patients with diabetes, prediabetes, and obesity is associated with severe COVID‐19	119
Extrapulmonary complications of COVID‐19: A multisystem disease?	117
The anti‐HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the SARSCoV‐2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID‐19 infe	116
Long COVID syndrome‐associated brain fog	114
Conjunctivitis and COVID‐19: A meta‐analysis	113
Omicron (BA.1) and sub‐variants (BA.1.1, BA.2, and BA.3) of SARS‐CoV‐2 spike infectivity and pathogenicity: A comparative sequence and structural‐based computational assessment	113
Epidemiological evidence for association between higher influenza vaccine uptake in the elderly and lower COVID‐19 deaths in Italy	111
Distinct viral clades of SARS‐CoV‐2: Implications for modeling of viral spread	110
Influenza and COVID‐19 coinfection: Report of six cases and review of the literature	109
Anxiety and depression symptoms after virological clearance of COVID‐19: A cross‐sectional study in Milan, Italy	108
Long COVID and chronic COVID syndromes	107
Multisystem inflammatory syndrome in children related to COVID‐19: A New York City experience	106
Safety of COVID‐19 vaccines	104
Obesity aggravates COVID‐19: An updated systematic review and meta‐analysis	103

Droplet digital PCR of viral ‎DNA/RNA, current progress, challenges, and future perspectives	102
Expression of the COVID‐19 receptor ACE2 in the human conjunctiva	100
Clinical performance of different SARS‐CoV‐2 IgG antibody tests	99
Asymptomatic SARS‐CoV‐2 infected case with viral detection positive in stool but negative in nasopharyngeal samples lasts for 42 days	98
The “post‐COVID” syndrome: How deep is the damage?	98
Autoimmune complications of COVID‐19	97
Non‐life‐threatening adverse effects with COVID‐19 mRNA‐1273 vaccine: A randomized, cross‐sectional study on healthcare workers with detailed self‐reported symptoms	96
Potential neuroinvasive pathways of SARS‐CoV‐2: Deciphering the spectrum of neurological deficit seen in coronavirus disease‐2019 (COVID‐19)	95
Where have all the viruses gone? Disappearance of seasonal respiratory viruses during the COVID‐19 pandemic	94
Risk factors prediction, clinical outcomes, and mortality in COVID‐19 patients	94
Anemia is associated with severe illness in COVID‐19: A retrospective cohort study	94
Increasing host cellular receptor—angiotensin‐converting enzyme 2 expression by coronavirus may facilitate 2019‐nCoV (or SARS‐CoV‐2) infection	93
Evolutionary dynamics of SARS‐CoV‐2 nucleocapsid protein and its consequences	93
Bacterial infections and patterns of antibiotic use in patients with COVID‐19	92
Targeting human TLRs to combat COVID‐19: A solution?	91
Hepatic involvement in COVID‐19 patients: Pathology, pathogenesis, and clinical implications	88
Retest positive for SARS‐CoV‐2 RNA of “recovered” patients with COVID‐19: Persistence, sampling issues, or re‐infection?	87
SARS‐CoV‐2 variants and vulnerability at the global level	85
Off‐label use of tocilizumab in patients with SARS‐CoV‐2 infection	85
Characterization of the significant decline in humoral immune response six months post‐SARS‐CoV‐2 mRNA vaccination: A systematic review	85
Evaluation of seven commercial RT‐PCR kits for COVID‐19 testing in pooled clinical specimens	84
Correlation between a quantitative anti‐SARS‐CoV‐2 IgG ELISA and neutralization activity	84
SARS‐CoV‐2: A comprehensive review from pathogenicity of the virus to clinical consequences	84
Comparative analysis of antiviral efficacy of FDA‐approved drugs against SARS‐CoV‐2 in human lung cells	84
Association between tuberculosis and COVID‐19 severity and mortality: A rapid systematic review and meta‐analysis	84
Causes of hypogeusia/hyposmia in SARS‐CoV2 infected patients	83
Genomic annotation and molecular evolution of monkeypox virus outbreak in 2022	83
Post‐COVID syndrome: A single‐center questionnaire study on 1007 participants recovered from COVID‐19	83
Human herpesvirus‐6, ‐7, and Epstein‐Barr virus reactivation in pityriasis rosea during COVID‐19	82
Hepatic complications of COVID‐19 and its treatment	82
The inflammatory markers of multisystem inflammatory syndrome in children (MIS‐C) and adolescents associated with COVID‐19: A meta‐analysis	82
Comparison of SARS‐CoV‐2 detection from nasopharyngeal swab samples by the Roche cobas 6800 SARS‐CoV‐2 test and a laboratory‐developed real‐time RT‐PCR test	82
Alert for non‐respiratory symptoms of coronavirus disease 2019 patients in epidemic period: A case report of familial cluster with three asymptomatic COVID‐19 patients	81
Role of toll‐like receptors in modulation of cytokine storm signaling in SARS‐CoV‐2‐induced COVID‐19	81
The outcome of COVID‐19 in patients with hematological malignancy	81
Effects of SARS‐CoV‐2 mutations on protein structures and intraviral protein–protein interactions	81
Obesity predisposes to the risk of higher mortality in young COVID‐19 patients	80
High prevalence of SARS‐CoV‐2 and influenza A virus (H1N1) coinfection in dead patients in Northeastern Iran	80
Elevated MUC1 and MUC5AC mucin protein levels in airway mucus of critical ill COVID‐19 patients	79
Concomitant neurological symptoms observed in a patient diagnosed with coronavirus disease 2019	79
Predictive values of blood urea nitrogen/creatinine ratio and other routine blood parameters on disease severity and survival of COVID‐19 patients	79
Efficacy of tocilizumab in COVID‐19: A systematic review and meta‐analysis	78
Clinical outcomes in COVID‐19 patients treated with tocilizumab: An individual patient data systematic review	78
Re‐emerging human monkeypox: A major public‐health debacle	78
Systematic analysis of ACE2 and TMPRSS2 expression in salivary glands reveals underlying transmission mechanism caused by SARS‐CoV‐2	78
Clinical and demographic characteristics of patients dying from COVID‐19 in Italy vs China	78
The global epidemic of SARS‐CoV‐2 variants and their mutational immune escape	77
SARS‐CoV‐2 and SARS‐CoV: Virtual screening of potential inhibitors targeting RNA‐dependent RNA polymerase activity (NSP12)	77
Extrapulmonary and atypical clinical presentations of COVID‐19	77
COVID‐19 vaccinations: The unknowns, challenges, and hopes	77
The first reactive arthritis case associated with COVID‐19	76
Cycle threshold values in RT‐PCR to determine dynamics of SARS‐CoV‐2 viral load: An approach to reduce the isolation period for COVID‐19 patients	76
Association of cardiac biomarkers and comorbidities with increased mortality, severity, and cardiac injury in COVID‐19 patients: A meta‐regression and decision tree analysis	75
COVID‐19 pneumonia treated with Sarilumab: A clinical series of eight patients	75
Elevated interleukin‐6 is associated with severity of COVID‐19: A meta‐analysis	74
The outbreak of SARS‐CoV‐2 Omicron lineages, immune escape, and vaccine effectivity	74
Recurrence of positive SARS‐CoV‐2 in patients recovered from COVID‐19	74
SARS‐CoV‐2 B.1.617 Indian variants: Are electrostatic potential changes responsible for a higher transmission rate?	73
Risk factors and outcomes of COVID‐19 in New York City; a retrospective cohort study	73
Gendered effects on inflammation reaction and outcome of COVID‐19 patients in Wuhan	73
Herpes zoster emergence following mRNA COVID‐19 vaccine	72
Analytical and clinical validation of an ELISA for specific SARS‐CoV‐2 IgG, IgA, and IgM antibodies	72
Clearance and persistence of SARS‐CoV‐2 RNA in patients with COVID‐19	72
Epidemiologic characteristics of cases with reinfection, recurrence, and hospital readmission due to COVID‐19: A systematic review and meta‐analysis	72
RNA‐dependent RNA polymerase of SARS‐CoV‐2 as a therapeutic target	72
Clinical study evaluating the efficacy of ivermectin in COVID‐19 treatment: A randomized controlled study	71
Epidemiological features and viral shedding in children with SARS‐CoV‐2 infection	71
SARS‐CoV‐2 S1 is superior to the RBD as a COVID‐19 subunit vaccine antigen	71
Decontamination of face masks with steam for mask reuse in fighting the pandemic COVID‐19: Experimental supports	71
Microstructure, pathophysiology, and potential therapeutics of COVID‐19: A comprehensive review	71
The global impact of COVID‐19 pandemic on the incidence of pediatric new‐onset type 1 diabetes and ketoacidosis: A systematic review and meta‐analysis	70
Immunoregulation with mTOR inhibitors to prevent COVID‐19 severity: A novel intervention strategy beyond vaccines and specific antiviral medicines	70
COVID‐19: A perspective on Africa's capacity and response	69
Impact of COVID‐19 in patients with concurrent co‐infections: A systematic review and meta‐analyses	69
Vitamin D deficiency is associated with COVID‐19 positivity and severity of the disease	69
Defining IL‐6 levels in healthy individuals: A meta‐analysis	69
Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID‐19): A systematic review and meta‐analysis	69
COVID‐19 and coagulation dysfunction in adults: A systematic review and meta‐analysis	69
Persistent viral RNA positivity during the recovery period of a patient with SARS‐CoV‐2 infection	68
Long‐term coexistence of SARS‐CoV‐2 with antibody response in COVID‐19 patients	68

Genomic and proteomic mutation landscapes of SARS‐CoV‐2	68
Coronapp: A web application to annotate and monitor SARS‐CoV‐2 mutations	68
COVID‐19 vaccines mix‐and‐match: The concept, the efficacy and the doubts	67
Obesity a predictor of outcomes of COVID‐19 hospitalized patients—A systematic review and meta‐analysis	67
Placental SARS‐CoV‐2 in a pregnant woman with mild COVID‐19 disease	66
Mortality risk with preadmission metformin use in patients with COVID‐19 and diabetes: A meta‐analysis	66
Omicron (B.1.1.529) variant of SARS‐CoV‐2: Concerns, challenges, and recent updates	66
Prolonged SARS‐CoV‐2 RNA detection in anal/rectal swabs and stool specimens in COVID‐19 patients after negative conversion in nasopharyngeal RT‐PCR test	66
Kidney involvement in COVID‐19 and its treatments	66
Positive result of Sars‐Cov‐2 in faeces and sputum from discharged patients with COVID‐19 in Yiwu, China	66
Serum KL‐6 concentrations as a novel biomarker of severe COVID‐19	66
Clinical neurophysiology and cerebrospinal liquor analysis to detect Guillain‐Barré syndrome and polyneuritis cranialis in COVID‐19 patients: A case series	65
Pooling of nasopharyngeal swab specimens for SARS‐CoV‐2 detection by RT‐PCR	64
Acute hypertriglyceridemia in patients with COVID‐19 receiving tocilizumab	64
Evidence of central nervous system infection and neuroinvasive routes, as well as neurological involvement, in the lethality of SARS‐CoV‐2 infection	64
Newly diagnosed diabetes mellitus, DKA, and COVID‐19: Causality or coincidence? A report of three cases	63
In silico analyses on the comparative sensing of SARS‐CoV‐2 mRNA by the intracellular TLRs of humans	63
SARS‐CoV‐2 coinfections: Could influenza and the common cold be beneficial?	63
Serological tests facilitate identification of asymptomatic SARS‐CoV‐2 infection in Wuhan, China	63
ACE2, TMPRSS2, and Furin variants and SARS‐CoV‐2 infection in Madrid, Spain	63
Understanding the pathophysiological changes via untargeted metabolomics in COVID‐19 patients	62
HIV/SARS‐CoV‐2 coinfection: A global perspective	62
The management of coronavirus disease 2019 (COVID‐19)	62
The dynamic changes of serum IgM and IgG against SARS‐CoV‐2 in patients with COVID‐19	62
Possible vertical transmission and antibodies against SARS‐CoV‐2 among infants born to mothers with COVID‐19: A living systematic review	61
Molecular evolutionary characteristics of SARS‐CoV‐2 emerging in the United States	61
Discharge may not be the end of treatment: Pay attention to pulmonary fibrosis caused by severe COVID‐19	61
Evaluating the efficiency of specimen pooling for PCR‐based detection of COVID‐19	61
Monkeypox: A potential global threat?	60
Polymorphisms of ACE (I/D) and ACE2 receptor gene (Rs2106809, Rs2285666) are not related to the clinical course of COVID‐19: A case study	60
Mutational and phylogenetic analyses of the two lineages of the Omicron variant	60
Optimization of group size in pool testing strategy for SARS‐CoV‐2: A simple mathematical model	60
The puzzling mutational landscape of the SARS‐2‐variant Omicron	60
Late onset infectious complications and safety of tocilizumab in the management of COVID‐19	60
COVID‐19: Herd immunity and convalescent plasma transfer therapy	60
In the age of Omicron variant: Paxlovid raises new hopes of COVID‐19 recovery	60
Antibody response to SARS‐CoV‐2 vaccination is extremely vivacious in subjects with previous SARS‐CoV‐2 infection	59
Characteristics of the first 1119 SARS‐CoV‐2 Omicron variant cases, in Marseille, France, November−December 2021	59
Risk factors for bacterial infections in patients with moderate to severe COVID‐19: A case‐control study	59
Safety and effectiveness of SARS‐CoV‐2 vaccines: A systematic review and meta‐analysis	59
Quantitation of antibodies against SARS‐CoV‐2 spike protein after two doses of CoronaVac in healthcare workers	59
SARS‐CoV‐2‐specific virulence factors in COVID‐19	58
COVID‐19: Consider IL‐6 receptor antagonist for the therapy of cytokine storm syndrome in SARS‐CoV‐2 infected patients	58
Omicron (B.1.1.529 variant of SARS‐CoV‐2); an emerging threat: Current global scenario	58
Meta‐analysis of chest CT features of patients with COVID‐19 pneumonia	58
Post‐COVID syndrome symptoms, functional disability, and clinical severity phenotypes in hospitalized and nonhospitalized individuals: A cross‐sectional evaluation from a community COVID rehabilitatio	58
Differences in incidence and fatality of COVID‐19 by SARS‐CoV‐2 Omicron variant versus Delta variant in relation to vaccine coverage: A world‐wide review	57
Low serum calcium and phosphorus and their clinical performance in detecting COVID‐19 patients	57
Transmission dynamics of SARS‐CoV‐2 within families with children in Greece: A study of 23 clusters	57
mTOR inhibition in COVID‐19: A commentary and review of efficacy in RNA viruses	57
Can steroids reverse the severe COVID‐19 induced “cytokine storm”?	56
Emerging evidence on Omicron (B.1.1.529) SARS‐CoV‐2 variant	56
Clinical characteristics of COVID‐19 in patients with preexisting ILD: A retrospective study in a single center in Wuhan, China	56
Public awareness about coronavirus vaccine, vaccine acceptance, and hesitancy	55
COVID‐19 in tuberculosis patients: A report of three cases	55
The COVID‐19 Yorkshire Rehabilitation Scale (C19‐YRS): Application and psychometric analysis in a post‐COVID‐19 syndrome cohort	55
SARS‐CoV‐2 antibodies: IgA correlates with severity of disease in early COVID‐19 infection	55
Duration of SARS‐CoV‐2 RNA shedding and factors associated with prolonged viral shedding in patients with COVID‐19	55
The electrostatic potential of the Omicron variant spike is higher than in Delta and Delta‐plus variants: A hint to higher transmissibility?	54
Bilateral anterior uveitis as a part of a multisystem inflammatory syndrome secondary to COVID‐19 infection	54
A third booster dose may be necessary to mitigate neutralizing antibody fading after inoculation with two doses of an inactivated SARS‐CoV‐2 vaccine	54
Clinical features of patients with coronavirus disease 2019 from a designated hospital in Beijing, China	54
The use of renin–angiotensin–aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID‐19 patients: A systematic review and meta‐analysis	53
Antibody responses against SARS‐CoV‐2 in COVID‐19 patients	53
Elevations of serum cancer biomarkers correlate with severity of COVID‐19	53
The role of type I interferon in the treatment of COVID‐19	53
Lowering the transmission and spread of human coronavirus	53
Twin combination of Omicron and Delta variants triggering a tsunami wave of ever high surges in COVID‐19 cases: A challenging global threat with a special focus on the Indian subcontinent	53
Dengue and COVID‐19, overlapping epidemics? An analysis from Colombia	53
Clinical features and outcome of HIV/SARS‐CoV‐2 coinfected patients in The Bronx, New York city	52
Viral coinfections in COVID‐19	52
SARS‐CoV‐2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two‐dose CoronaVac vaccine regimen	52
Use of chlorhexidine to eradicate oropharyngeal SARS‐CoV‐2 in COVID‐19 patients	52
Consider TLR5 for new therapeutic development against COVID‐19	52
COVID‐19 related fatigue: Which role for rehabilitation in post‐COVID‐19 patients? A case series	51
Detection of SARS‐CoV‐2 Omicron (B.1.1.529) variant has created panic among the people across the world: What should we do right now?	51
Gastroenterology manifestations and COVID‐19 outcomes: A meta‐analysis of 25,252 cohorts among the first and second waves	50
Sex and gender differences in the outcome of patients with COVID‐19	50
The clinical characteristic of eight patients of COVID‐19 with positive RT‐PCR test after discharge	50
Could HIV infection alter the clinical course of SARS‐CoV‐2 infection? When less is better	50
Co‐infection with COVID‐19 and influenza A virus in two died patients with acute respiratory syndrome, Bojnurd, Iran	50
The clinical characteristics of pediatric inpatients with SARS‐CoV‐2 infection: A meta‐analysis and systematic review	50
Soluble angiotensin‐converting enzyme 2 is transiently elevated in COVID‐19 and correlates with specific inflammatory and endothelial markers	50
Attaching a stigma to the LGBTQI+ community should be avoided during the monkeypox epidemic	50
Proportion of asymptomatic infection and nonsevere disease caused by SARS‐CoV‐2 Omicron variant: A systematic review and analysis	50
Fetal and placental infection with SARS‐CoV‐2 in early pregnancy	50
HIV/SARS‐CoV‐2 coinfected patients in Istanbul, Turkey	49
Molnupiravir: A lethal mutagenic drug against rapidly mutating severe acute respiratory syndrome coronavirus 2—A narrative review	49
Detection of highly muted coronavirus variant Omicron (B.1.1.529) is triggering the alarm for South Asian countries: Associated risk factors and preventive actions	49
COVID‐19 and liver dysfunction: A systematic review and meta‐analysis of retrospective studies	49
Rhinovirus spread in children during the COVID‐19 pandemic despite social restrictions—A nationwide register study in Finland	48
Increase in COVID‐19 cases and case‐fatality and case‐recovery rates in Europe: A cross‐temporal meta‐analysis	48
Role of nonstructural proteins in the pathogenesis of SARS‐CoV‐2	48
Higher levels of IL‐6 early after tocilizumab distinguish survivors from nonsurvivors in COVID‐19 pneumonia: A possible indication for deeper targeting of IL‐6	48
Coronavirus genomic nsp14‐ExoN, structure, role, mechanism, and potential application as a drug target	48